1. Home
  2. BMRN vs CNA Comparison

BMRN vs CNA Comparison

Compare BMRN & CNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BMRN
  • CNA
  • Stock Information
  • Founded
  • BMRN 1996
  • CNA 1853
  • Country
  • BMRN United States
  • CNA United States
  • Employees
  • BMRN N/A
  • CNA N/A
  • Industry
  • BMRN Biotechnology: Pharmaceutical Preparations
  • CNA Property-Casualty Insurers
  • Sector
  • BMRN Health Care
  • CNA Finance
  • Exchange
  • BMRN Nasdaq
  • CNA Nasdaq
  • Market Cap
  • BMRN 12.1B
  • CNA 13.2B
  • IPO Year
  • BMRN 1999
  • CNA N/A
  • Fundamental
  • Price
  • BMRN $54.97
  • CNA $46.03
  • Analyst Decision
  • BMRN Buy
  • CNA Sell
  • Analyst Count
  • BMRN 22
  • CNA 2
  • Target Price
  • BMRN $93.43
  • CNA $50.50
  • AVG Volume (30 Days)
  • BMRN 2.2M
  • CNA 560.6K
  • Earning Date
  • BMRN 08-04-2025
  • CNA 07-28-2025
  • Dividend Yield
  • BMRN N/A
  • CNA 8.28%
  • EPS Growth
  • BMRN 152.82
  • CNA N/A
  • EPS
  • BMRN 2.71
  • CNA 3.28
  • Revenue
  • BMRN $2,950,227,000.00
  • CNA $14,453,000,000.00
  • Revenue This Year
  • BMRN $12.23
  • CNA N/A
  • Revenue Next Year
  • BMRN $9.99
  • CNA $24.00
  • P/E Ratio
  • BMRN $20.28
  • CNA $14.14
  • Revenue Growth
  • BMRN 19.36
  • CNA 6.34
  • 52 Week Low
  • BMRN $52.93
  • CNA $44.42
  • 52 Week High
  • BMRN $94.85
  • CNA $52.36
  • Technical
  • Relative Strength Index (RSI)
  • BMRN 40.74
  • CNA 45.82
  • Support Level
  • BMRN $53.76
  • CNA $45.26
  • Resistance Level
  • BMRN $56.25
  • CNA $46.41
  • Average True Range (ATR)
  • BMRN 1.26
  • CNA 0.74
  • MACD
  • BMRN 0.06
  • CNA 0.07
  • Stochastic Oscillator
  • BMRN 28.09
  • CNA 55.98

About BMRN BioMarin Pharmaceutical Inc.

BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.

About CNA CNA Financial Corporation

CNA Financial Corporation (CNAF) is an insurance holding company that provides commercial property and casualty insurance. The company operates under five segments: Specialty, Commercial and International being its core business, and two segments for its non-core businesses, which are Life and Group and Corporate and Other. CNAF, through its segments, provides professional, financial, specialty property, and casualty products to small businesses and medium-scale organizations. It has its business spread across Continental Europe, United Kingdom, and Canada. The majority of the revenues are generated from the Specialty and Commercial segment of the business.

Share on Social Networks: